Skip to content
10-Q

Quarterly Report

Corvus Pharmaceuticals, Inc. CRVS

0001558370-25-006966

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 8, 2025 77.11M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $5M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $8.74M
Current Liabilities Q1 2025 · Mar 31, 2025 $9.28M
Current Liabilities Q1 2025 · Dec 31, 2024 $35.4M
Total Liabilities Q1 2025 · Mar 31, 2025 $10.11M
Total Liabilities Q1 2025 · Dec 31, 2024 $36.34M
Current Assets Q1 2025 · Mar 31, 2025 $45.49M
Current Assets Q1 2025 · Dec 31, 2024 $54.41M
Total Assets Q1 2025 · Mar 31, 2025 $59.44M
Total Assets Q1 2025 · Dec 31, 2024 $68.91M
Shares Diluted Q1 2025 · Mar 31, 2024 49.04M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$5.16M
Stockholders Equity Q1 2025 · Mar 31, 2024 $33.36M
Stockholders Equity Q1 2025 · Dec 31, 2023 $38.68M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.12
Eps Basic Q1 2025 · Mar 31, 2024 −$0.12
Sga Expense Q1 2025 · Mar 31, 2024 $2.18M
Rd Expense Q1 2025 · Mar 31, 2024 $4.08M
Net Income Q1 2025 · Mar 31, 2024 −$5.7M
Operating Income Q1 2025 · Mar 31, 2024 −$6.25M